

Financial news for PTBI dated on 2015-06-19: PlasmaTech Biopharmaceuticals To Change Name To Abeona Therapeutics To Show Broad Rare Disease Commitment

Financial news for PTBI dated on 2015-06-15: Benzinga's Top #PreMarket Gainers

Financial news for PTBI dated on 2015-06-15: PlasmaTech Biopharma Shares Rise 4% Premarket Following Announcement of License Deal for Gene Therapy in Fanconi Anemia, CRISPR/Cas9-Based Technology Platform

Financial news for PTBI dated on 2015-06-15: PlasmaTech Biopharma Reports License Deal for Gene Therapy in Fanconi Anemia, CRISPR/Cas9-Based Technology Platform

Financial news for PTBI dated on 2015-06-15: PlasmaTech Biopharmaceuticals Expands Rare Disease Pipeline With License Agreement for Gene Therapy in Fanconi Anemia & CRISPR/Cas9-Based Technology Platform for Rare Blood Disorders

Financial news for PTBI dated on 2015-06-11: Roth Capital: Buy Plasmatech Bio, It's Worth \$16/Share And Is Assembling A 'World-Class' Portfolio

Financial news for PTBI dated on 2015-06-11: Benzinga's Top Initiations

Financial news for PTBI dated on 2015-06-11: Roth Capital Initiates Plasmatech With Buy

Financial news for PTBI dated on 2015-06-11: Roth Capital Initiates Coverage on PlasmaTech at Buy, Announces \$16.00 PT

Financial news for PTBI dated on 2015-06-08: Morning Market Gainers

Financial news for PTBI dated on 2015-06-08: PlasmaTech Biopharmaceuticals Reports License Agreement for AAV Gene Therapy to Treat Patients With Juvenile Batten Disease

Financial news for PTBI dated on 2015-05-28: TheStreetSweeper releases a new investigative report: PlasmaTech Biopharmaceuticals

Financial news for PTBI dated on 2015-05-20: PlasmaTech Biopharmaceuticals Reports Orphan Drug and Rare Pediatric Disease Designations From FDA

Financial news for PTBI dated on 2015-05-18: Benzinga's Top Initiations

Financial news for PTBI dated on 2015-05-18: H.C Wainwright Initiates Coverage on PlasmaTech at Buy, Announces \$15.00 PT

Financial news for PTBI dated on 2015-05-15: Plasmatech Biopharmaceuticals Files for Possible Resale of 1.9M Shares by Selling Stockholder

Financial news for PTBI dated on 2015-05-14: UPDATE: PlasmaTech Biopharmaceuticals Shares Rise 7.5% Premarket as Co Announces Completion of Sanfilippo Syndrome Toxicology Studies at American Society of Gene and Cell Therapy Annual Meeting

Financial news for PTBI dated on 2015-05-07: Morning Market Gainers

Financial news for PTBI dated on 2015-05-06: Benzinga's M&A Chatter for Wednesday May 6, 2015

Financial news for PTBI dated on 2015-05-06: Plasmatech Biopharma Announces \$10M Private Placement

Financial news for PTBI dated on 2015-05-06: Morning Market Gainers

Financial news for PTBI dated on 2015-05-06: UPDATE: PlasmaTech Biopharmaceuticals Shares Rise 46% Premarket Following Announcement of Abeona Therapeutics Acquisition

Financial news for PTBI dated on 2015-05-06: US Stock Futures Jump Ahead Of ADP Report

Financial news for PTBI dated on 2015-05-06: PlasmaTech Biopharmaceuticals Shares Rise 13% Premarket Following Announcement of Abeona Therapeutics Acquisition

Financial news for PTBI dated on 2015-05-06: PlasmaTech Biopharmaceuticals to Acquire Abeona Therapeutics LLC for ~3.979M Shares of PTBI Stock at Closing

Financial news for PTBI dated on 2015-05-06: PlasmaTech Biopharmaceuticals Announces Agreement to Acquire Abeona Therapeutics

Financial news for PTBI dated on 2015-05-05: Morning Market Gainers

Financial news for PTBI dated on 2015-05-05: PlasmaTech Biopharmaceuticals Shares Rise 50% Premarket Following Report of Soros Stake

Financial news for PTBI dated on 2015-05-04: Shares of PlasmaTech Biopharma Moving Higher as 13G Filing from George Soros' Soros Fund Mgmt Shows New 5.17% Stake in Co.

Financial news for PTBI dated on 2015-04-07: PlasmaTech Biopharmaceuticals Appoints Alpha-1 Expert Robert Sandhaus, MD, Ph.D. To Its Scientific Advisory Board

Financial news for PTBI dated on 2015-04-02: PlasmaTech Biopharmaceuticals' Announces \$5M Private Placement

Financial news for PTBI dated on 2015-03-05: PlasmaTech Biopharma ANnounces Enrollment of MuGard Trial For Afinitor